<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02270242</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 14-1383</org_study_id>
    <nct_id>NCT02270242</nct_id>
  </id_info>
  <brief_title>Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention</brief_title>
  <acronym>TWILIGHT</acronym>
  <official_title>Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the use of ticagrelor alone versus ticagrelor and&#xD;
      aspirin together. Both ticagrelor and aspirin stop platelets from sticking together and&#xD;
      forming a blood clot that could block blood flow to the heart. This study will look to&#xD;
      determine the effectiveness and safety of ticagrelor alone, compared to ticagrelor plus&#xD;
      aspirin in reducing clinically relevant bleeding and in reducing ischemic adverse events&#xD;
      among high-risk patients who have had a percutaneous intervention with at least one&#xD;
      drug-eluting stent. A patient is considered high-risk if they meet certain clinical and/or&#xD;
      anatomic criteria.&#xD;
&#xD;
      Up to 9000 subjects will be enrolled at the time of their index PCI. Subjects meeting&#xD;
      randomization eligibility criteria at 3 months post enrollment will be randomized to either&#xD;
      ticagrelor plus aspirin or ticagrelor plus placebo for an additional 12 months. Follow-up&#xD;
      clinic visits will be performed at 3 months, 9 months and 15 months post enrollment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective, blinded dual-arm study. Up to 9000 high-risk patients who&#xD;
      have undergone successful PCI with at least one locally approved drug eluting stent&#xD;
      discharged on DAPT with aspirin and ticagrelor of at least 3 months intended duration from&#xD;
      centers still to be determined in the U.S., Canada, Europe and Asia. The primary objective of&#xD;
      this study is to determine the impact of antiplatelet monotherapy with ticagrelor alone&#xD;
      versus DAPT with ticagrelor plus aspirin for 12 months in reducing clinically relevant&#xD;
      bleeding (efficacy) among high-risk patients undergoing PCI who have completed a 3-month&#xD;
      course of aspirin plus ticagrelor. The secondary objective of this study is to determine the&#xD;
      impact of antiplatelet monotherapy with ticagrelor alone versus DAPT with ticagrelor plus&#xD;
      aspirin for 12 months in reducing major ischemic adverse events (safety) among high-risk&#xD;
      patients undergoing PCI who have completed a 3-month course of aspirin plus ticagrelor.&#xD;
&#xD;
      Exploratory objectives include assessing the comparative safety and efficacy of the different&#xD;
      DAPT regimens for individual components of the primary efficacy and secondary safety&#xD;
      objectives.&#xD;
&#xD;
      The primary analysis for TWILIGHT will be performed independently by the London School of&#xD;
      Hygiene and Tropical Medicine&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 10, 2019</completion_date>
  <primary_completion_date type="Actual">July 10, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With BARC Type 2, 3, or 5</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemic Episode</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9006</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Interventional Cardiology</condition>
  <arm_group>
    <arm_group_label>Aspirin + Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Ticagrelor</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Aspirin + Ticagrelor</arm_group_label>
    <other_name>Ecotrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor</intervention_name>
    <arm_group_label>Aspirin + Ticagrelor</arm_group_label>
    <arm_group_label>Placebo + Ticagrelor</arm_group_label>
    <other_name>Brilinta</other_name>
    <other_name>Brilique</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  High-risk patients who have undergone successful PCI with at least one locally&#xD;
             approved drug eluting stent discharged on DAPT with aspirin and ticagrelor of at least&#xD;
             3 months intended duration will be eligible for the TWILIGHT study.&#xD;
&#xD;
          -  Enrollment into the study will require meeting at least one clinical inclusion, one&#xD;
             angiographic inclusion and none of the exclusion criteria.&#xD;
&#xD;
        Clinical Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients ≥ 65 years of age&#xD;
&#xD;
          -  Female gender&#xD;
&#xD;
          -  Troponin Positive acute coronary syndrome&#xD;
&#xD;
          -  Established vascular disease defined as previous MI, documented PAD or CAD/PAD&#xD;
             revascularization&#xD;
&#xD;
          -  Diabetes mellitus treated with medications (oral hypoglycemic, subcutaneous injection&#xD;
             of insulin)&#xD;
&#xD;
          -  Chronic kidney disease defined as an estimated glomerular filtration rate (eGFR) &lt; 60&#xD;
             ml/min/1.73m2 or creatinine clearance (CrCl) &lt; 60 ml/min&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          -  Multivessel coronary artery disease&#xD;
&#xD;
          -  Target lesion requiring total stent length &gt;30 mm&#xD;
&#xD;
          -  Thrombotic target lesion(s)&#xD;
&#xD;
          -  Bifurcation lesions with Medina X,1,1 classification requiring at least 2 stents&#xD;
&#xD;
          -  Left main (≥50%) or proximal LAD (≥70%) lesion&#xD;
&#xD;
          -  Calcified target lesion(s) requiring atherectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under 18 years of age&#xD;
&#xD;
          -  Contraindication to aspirin&#xD;
&#xD;
          -  Contraindication to ticagrelor&#xD;
&#xD;
          -  Planned surgery within 90 days&#xD;
&#xD;
          -  Planned coronary revascularization (surgical or percutaneous) within 90 days&#xD;
&#xD;
          -  Need for chronic oral anticoagulation&#xD;
&#xD;
          -  Prior stroke&#xD;
&#xD;
          -  Dialysis-dependent renal failure&#xD;
&#xD;
          -  Active bleeding or extreme-risk for major bleeding (e.g. active peptic ulcer disease,&#xD;
             gastrointestinal pathology with a raised risk for bleeding, malignancies with a raised&#xD;
             risk for bleeding)&#xD;
&#xD;
          -  Salvage PCI or STEMI presentation.&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  Life expectancy &lt; 1 year&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent&#xD;
&#xD;
          -  Women of child bearing potential. Defined: a woman is considered potential (WOBCP)&#xD;
             following menarche and until becoming post-menopausal unless permanently sterile.&#xD;
             Permanent sterilization methods include hysterectomy, bilateral salpingectomy and&#xD;
             bilateral oophorectomy. a postmenopausal state is defined as no menses for 12 months&#xD;
             without an alternative medical cause.&#xD;
&#xD;
          -  Fibrinolytic therapy within 24 hours of index PCI&#xD;
&#xD;
          -  Concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer&#xD;
&#xD;
          -  Platelet count &lt; 100,000 mm3&#xD;
&#xD;
          -  Requiring ongoing treatment with aspirin ≥ 325 mg daily&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roxana Mehran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Usman Baber, MD</last_name>
    <role>Study Director</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roxana Mehran, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007 Aug 14;116(7):e148-304. Epub 2007 Aug 6. Erratum in: Circulation. 2008 Mar 4;117(9):e180.</citation>
    <PMID>17679616</PMID>
  </reference>
  <reference>
    <citation>Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004 Aug 3;110(5):588-636. Erratum in: Circulation. 2005 Apr 19;111(15):2013.</citation>
    <PMID>15289388</PMID>
  </reference>
  <reference>
    <citation>King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL; ACC/AHA/SCAI, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008 Jan 15;51(2):172-209. doi: 10.1016/j.jacc.2007.10.002.</citation>
    <PMID>18191745</PMID>
  </reference>
  <reference>
    <citation>Dupont AG, Gabriel DA, Cohen MG. Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thromb Res. 2009 May;124(1):6-13. doi: 10.1016/j.thromres.2009.01.014. Epub 2009 Mar 25. Review.</citation>
    <PMID>19324398</PMID>
  </reference>
  <reference>
    <citation>Geisler T, Zürn C, Simonenko R, Rapin M, Kraibooj H, Kilias A, Bigalke B, Stellos K, Schwab M, May AE, Herdeg C, Gawaz M. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J. 2010 Jan;31(1):59-66. doi: 10.1093/eurheartj/ehp402. Epub 2009 Oct 6.</citation>
    <PMID>19812059</PMID>
  </reference>
  <reference>
    <citation>Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Büttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006 Nov 7;48(9):1742-50. Epub 2006 Oct 17.</citation>
    <PMID>17084243</PMID>
  </reference>
  <reference>
    <citation>Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009 Jan 20;119(2):237-42. doi: 10.1161/CIRCULATIONAHA.108.812636. Epub 2008 Dec 31.</citation>
    <PMID>19118249</PMID>
  </reference>
  <reference>
    <citation>Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006 May;27(10):1166-73. Epub 2006 Apr 18.</citation>
    <PMID>16621870</PMID>
  </reference>
  <reference>
    <citation>Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008 Jan;29(1):21-30. Epub 2007 Nov 30.</citation>
    <PMID>18055486</PMID>
  </reference>
  <reference>
    <citation>Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001-15. Epub 2007 Nov 4.</citation>
    <PMID>17982182</PMID>
  </reference>
  <reference>
    <citation>van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005 Apr;31(2):195-204. Review.</citation>
    <PMID>15852223</PMID>
  </reference>
  <reference>
    <citation>Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006 May;27(9):1038-47. Epub 2006 Feb 13.</citation>
    <PMID>16476694</PMID>
  </reference>
  <reference>
    <citation>Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007 Nov 6;50(19):1852-6. Epub 2007 Oct 23.</citation>
    <PMID>17980251</PMID>
  </reference>
  <reference>
    <citation>Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. doi: 10.1016/j.jacc.2012.03.050.</citation>
    <PMID>22789884</PMID>
  </reference>
  <reference>
    <citation>Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.</citation>
    <PMID>19717846</PMID>
  </reference>
  <reference>
    <citation>Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW, Kim HS, Park SJ, Kastrati A, de Waha A, Krishnan P, Moreno P, Sweeny J, Kim MC, Suleman J, Pyo R, Wiley J, Kovacic J, Kini AS, Dangas GD. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011 Oct 4;58(15):1569-77. doi: 10.1016/j.jacc.2011.06.049. Epub 2011 Sep 14.</citation>
    <PMID>21924575</PMID>
  </reference>
  <reference>
    <citation>Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmão M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL; OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013 Dec 18;310(23):2510-22. doi: 10.1001/jama.2013.282183.</citation>
    <PMID>24177257</PMID>
  </reference>
  <reference>
    <citation>Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fucà G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012 Apr 24;125(16):2015-26. doi: 10.1161/CIRCULATIONAHA.111.071589. Epub 2012 Mar 21.</citation>
    <PMID>22438530</PMID>
  </reference>
  <reference>
    <citation>Brar SS, Kim J, Brar SK, Zadegan R, Ree M, Liu IL, Mansukhani P, Aharonian V, Hyett R, Shen AY. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol. 2008 Jun 10;51(23):2220-7. doi: 10.1016/j.jacc.2008.01.063.</citation>
    <PMID>18534267</PMID>
  </reference>
  <reference>
    <citation>Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012 Jan 24;125(3):505-13. doi: 10.1161/CIRCULATIONAHA.111.059022. Epub 2011 Dec 16.</citation>
    <PMID>22179532</PMID>
  </reference>
  <reference>
    <citation>Chirumamilla AP, Maehara A, Mintz GS, Mehran R, Kanwal S, Weisz G, Hassanin A, Hakim D, Guo N, Baber U, Pyo R, Moses JW, Fahy M, Kovacic JC, Dangas GD. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging. 2012 May;5(5):540-9. doi: 10.1016/j.jcmg.2011.12.019.</citation>
    <PMID>22595163</PMID>
  </reference>
  <reference>
    <citation>Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449.</citation>
    <PMID>21670242</PMID>
  </reference>
  <reference>
    <citation>Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006 Oct;152(4):627-35.</citation>
    <PMID>16996826</PMID>
  </reference>
  <reference>
    <citation>Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.</citation>
    <PMID>17470709</PMID>
  </reference>
  <reference>
    <citation>Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. Circulation. 2012 Oct 16;126(16):2020-35. doi: 10.1161/CIR.0b013e31826e1058. Epub 2012 Aug 24.</citation>
    <PMID>22923432</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <results_first_submitted>July 10, 2020</results_first_submitted>
  <results_first_submitted_qc>August 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2020</results_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Roxana Mehran</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PCI</keyword>
  <keyword>DAPT</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>aspirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02270242/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From July 2015 through December 2017, 9006 patients were enrolled, and 7119 underwent randomization after 3 months</recruitment_details>
      <pre_assignment_details>1887 excluded from randomization (106 lost to follow up, 243 had adverse events between enrollment and randomization: a) myocardial infarction, stroke or death, b) revascularizations, and/or c) BARC type 3b or higher bleedings, 1148 were not adherent to DAPT, 267 withdrew consent or declined to participate, and 123 had other reasons.)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo + Ticagrelor</title>
          <description>placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months</description>
        </group>
        <group group_id="P2">
          <title>Aspirin + Ticagrelor</title>
          <description>enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3555"/>
                <participants group_id="P2" count="3564"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3496"/>
                <participants group_id="P2" count="3511"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo + Ticagrelor</title>
          <description>placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months</description>
        </group>
        <group group_id="B2">
          <title>Aspirin + Ticagrelor</title>
          <description>enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3555"/>
            <count group_id="B2" value="3564"/>
            <count group_id="B3" value="7119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="10.3"/>
                    <measurement group_id="B2" value="65.1" spread="10.4"/>
                    <measurement group_id="B3" value="65.1" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="846"/>
                    <measurement group_id="B2" value="852"/>
                    <measurement group_id="B3" value="1698"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2709"/>
                    <measurement group_id="B2" value="2712"/>
                    <measurement group_id="B3" value="5421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Nonwhite race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1110"/>
                    <measurement group_id="B2" value="1086"/>
                    <measurement group_id="B3" value="2196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2445"/>
                    <measurement group_id="B2" value="2478"/>
                    <measurement group_id="B3" value="4923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>North America</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1484"/>
                    <measurement group_id="B2" value="1488"/>
                    <measurement group_id="B3" value="2972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1251"/>
                    <measurement group_id="B2" value="1258"/>
                    <measurement group_id="B3" value="2509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="512"/>
                    <measurement group_id="B2" value="516"/>
                    <measurement group_id="B3" value="1028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="5.5"/>
                    <measurement group_id="B2" value="28.5" spread="5.6"/>
                    <measurement group_id="B3" value="28.6" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1319"/>
                    <measurement group_id="B2" value="1301"/>
                    <measurement group_id="B3" value="2620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes treated with Insulin</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="335"/>
                    <measurement group_id="B2" value="374"/>
                    <measurement group_id="B3" value="709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Kidney Disease (CKD)</title>
          <population>multinational trial involving over 9000 patients across 187 sites - some variables were missing and not entered into the system in some of the sites. active efforts were made to retrieve these variables but in some cases it was not possible.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3410"/>
                    <count group_id="B2" value="3425"/>
                    <count group_id="B3" value="6835"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="572"/>
                    <measurement group_id="B2" value="573"/>
                    <measurement group_id="B3" value="1145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anemia</title>
          <population>multinational trial involving over 9000 patients across 187 sites - some variables were missing and not entered into the system in some of the sites. active efforts were made to retrieve these variables but in some cases it was not possible.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3405"/>
                    <count group_id="B2" value="3423"/>
                    <count group_id="B3" value="6828"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="675"/>
                    <measurement group_id="B2" value="654"/>
                    <measurement group_id="B3" value="1329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current smoker</title>
          <population>multinational trial involving over 9000 patients across 187 sites - some variables were missing and not entered into the system in some of the sites. active efforts were made to retrieve these variables but in some cases it was not possible.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3553"/>
                    <count group_id="B2" value="3562"/>
                    <count group_id="B3" value="7115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="726"/>
                    <measurement group_id="B2" value="822"/>
                    <measurement group_id="B3" value="1548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypercholesterolemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2157"/>
                    <measurement group_id="B2" value="2146"/>
                    <measurement group_id="B3" value="4303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <population>multinational trial involving over 9000 patients across 187 sites - some variables were missing and not entered into the system in some of the sites. active efforts were made to retrieve these variables but in some cases it was not possible.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3554"/>
                    <count group_id="B2" value="3563"/>
                    <count group_id="B3" value="7117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2580"/>
                    <measurement group_id="B2" value="2574"/>
                    <measurement group_id="B3" value="5154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peripheral Arterial Disease (PAD)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="245"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Myocardial Infarction (MI)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1020"/>
                    <measurement group_id="B2" value="1020"/>
                    <measurement group_id="B3" value="2040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Percutaneous Coronary Intervention (PCI)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1502"/>
                    <measurement group_id="B2" value="1496"/>
                    <measurement group_id="B3" value="2998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Coronary Artery Bypass Graft (CABG)</title>
          <population>multinational trial involving over 9000 patients across 187 sites - some variables were missing and not entered into the system in some of the sites. active efforts were made to retrieve these variables but in some cases it was not possible.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3554"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="348"/>
                    <measurement group_id="B3" value="710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Multivessel Coronary Artery Disease (CAD)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2272"/>
                    <measurement group_id="B2" value="2194"/>
                    <measurement group_id="B3" value="4466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Major Bleeding Event</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3555"/>
                    <count group_id="B2" value="3564"/>
                    <count group_id="B3" value="7119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indication for PCI</title>
          <population>multinational trial involving over 9000 patients across 187 sites - some variables were missing and not entered into the system in some of the sites. active efforts were made to retrieve these variables but in some cases it was not possible.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asymptomatic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3554"/>
                    <count group_id="B2" value="3563"/>
                    <count group_id="B3" value="7117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable angina</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3554"/>
                    <count group_id="B2" value="3563"/>
                    <count group_id="B3" value="7117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1047"/>
                    <measurement group_id="B2" value="999"/>
                    <measurement group_id="B3" value="2046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unstable angina</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3554"/>
                    <count group_id="B2" value="3563"/>
                    <count group_id="B3" value="7117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1249"/>
                    <measurement group_id="B2" value="1245"/>
                    <measurement group_id="B3" value="2494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NSTEMI (non-ST-segment elevation MI)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3554"/>
                    <count group_id="B2" value="3563"/>
                    <count group_id="B3" value="7117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1024"/>
                    <measurement group_id="B2" value="1096"/>
                    <measurement group_id="B3" value="2120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With BARC Type 2, 3, or 5</title>
        <description>Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding).</description>
        <time_frame>12 months after randomization</time_frame>
        <population>Data for the intention-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Ticagrelor</title>
            <description>placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Aspirin + Ticagrelor</title>
            <description>enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With BARC Type 2, 3, or 5</title>
          <description>Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding).</description>
          <population>Data for the intention-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3555"/>
                <count group_id="O2" value="3564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemic Episode</title>
        <description>Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke.</description>
        <time_frame>12 months after randomization</time_frame>
        <population>data for the per-protocol population , i.e., the participants who underwent randomization and had no major deviations from the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Ticagrelor</title>
            <description>placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Aspirin + Ticagrelor</title>
            <description>enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemic Episode</title>
          <description>Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke.</description>
          <population>data for the per-protocol population , i.e., the participants who underwent randomization and had no major deviations from the protocol.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3524"/>
                <count group_id="O2" value="3515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>All bleeding AE were reported in the intention-to-treat (ITT) cohort. - Placebo + Ticagrelor (N=3555) and Aspirin + Ticagrelor (N=3564)&#xD;
All ischemic AE were reported in the per protocol (PP) cohort. - Placebo + Ticagrelor (N=3524) and Aspirin + Ticagrelor (N=3515)&#xD;
All-cause mortality were reported in the per protocol (PP) cohort. - Placebo + Ticagrelor (N=3524) and Aspirin + Ticagrelor (N=3515)</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo + Ticagrelor</title>
          <description>placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months</description>
        </group>
        <group group_id="E2">
          <title>Aspirin + Ticagrelor</title>
          <description>enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="3524"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="3515"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="262" subjects_at_risk="3555"/>
                <counts group_id="E2" subjects_affected="370" subjects_at_risk="3564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="3524"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="3515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Stent Thrombosis, definite or probable</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="3524"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="3515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="3524"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3515"/>
              </event>
              <event>
                <sub_title>BARC 235</sub_title>
                <description>BARC type 2, 3, 5 bleeding</description>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="3555"/>
                <counts group_id="E2" subjects_affected="250" subjects_at_risk="3564"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3555"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3564"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator remains responsible &amp; has final approval for any publication and can publish/present results but shall submit manuscript/material proposed for publication/presentation relating to results to AZ for review ≤45 days prior to submission. AZ has 45 days to respond with comments. If requested by AZ, Investigator shall delay submission for further period ≤45 days, for deemed appropriate measures to establish/preserve parties' proprietary rights in intellectual property disclosed.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations include lack of power to detect differences in the risk of important yet rare clinical events, e.g stent thrombosis and stroke; and trial may not be generalizable to all patients undergoing PCI due to high risk criteria.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Roxana Mehran</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-659-9691</phone>
      <email>roxana.mehran@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

